Monte Rosa Therapeutics, Inc. announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a price of $24.00 per share, expecting gross proceeds of approximately $300 million. The offering is set to close on January 12, 2026, with an option for underwriters to purchase additional shares. Jefferies, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering. Monte Rosa is a biotech company developing molecular glue degrader medicines for various diseases, with ongoing collaborations in immunology, oncology, and neurology.

Investors can contact [email protected], while media inquiries can be directed to [email protected]. Monte Rosa Therapeutics is focused on developing highly selective molecular glue degrader medicines using their QuEEN™ discovery engine. Forward-looking statements in the press release outline the company’s expectations regarding the public offering and caution investors about risks and uncertainties related to market conditions. Monte Rosa disclaims any obligation to update forward-looking statements.

Read more at GlobeNewswire: Monte Rosa Therapeutics Announces Pricing of $300 Million